Safety and immunogenicity of Brucella suis strain S2 ghosts
MIAO Yu-qiang1, LIU Jun2, SUN Yang2, JI Xue2, ZHU Ling-wei2, ZHOU Wei2, GUO Xue-jun2, LIU Shuang2, CHEN Ping1, FENG Shu-zhang2
1. Food Science and Engineering, Jilin Agricultural University, Changchun 130118, China; 2. Institute of Military Veterinary Science, the Academy of Military Medical Science of PLA, Changchun 130122, China
Abstract：With the purpose of investigating the safety and immunogenicity of Brucella suis strain S2 bacterial ghosts as a vaccine candidate, the recombinant strain S2(pBBR1MCS-E) was used for production of B. suis ghosts (BSG). The safety and immunogenicity of BSG were evaluated by using a murine model. The results suggested that BSG was as safe as formalin-killed B. suis. Compared with the B. suis strain S2, BSG demonstrated similar capacity of inducing pathogen-specific serum IgG antibody response, spleen CD3+ and CD4+ T cell responses, as the attenuated B. suis live vaccine. The results of mice immunization and infection showed that BSG could significantly reduce the number of bacteria in the spleens. These data suggest that Brucella ghosts could confer protection against Brucella infection and may be developed as a new vaccine candidate against Brucella infection.
[1] Cutler SJ, Whatmore AM, Commander NJ. Brucellosis new aspects of an old disease[J]. J Appl Microbiol, 2005, 98(6): 1270-1281. doi:10.1111/j.1365-2672.2005.02622.x [2] Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans[J]. FEMS Microbiol Rev, 2010, 34(3): 379-394. doi:10.1111/j.1574-6976.2010.00211.x [3] Deqiu S, Donglou X, Jiming Y. Epidemiology and control of brucellosis in China[J]. Vet Microbiol, 2002, 90(1-4): 165-182. doi:10.1016/S0378-1135(02)00252-3 [4] Qiu J, Wang W, Wu J, et al. Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies[J]. PLoS One, 2012, 7(3): e34246. doi:10.1371/journal.pone.0034246 [5] Zhang WY, Guo WD, Sun SH, et al. Human brucellosis, Inner Mongolia, China[J]. Emerg Infect Dis, 2010, 16(12): 2001-2003. doi:10.3201/eid1612.091081 [6] Tabynov K, Sansyzbay A, Kydyrbayev Z, et al. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection[J]. Virol J, 2014, 11: 69. doi:10.1186/1743-422X-11-69 [7] Lubitz P, Mayr UB, Lubitz W. Applications of bacterial ghosts in biomedicine[J]. Adv Exp Med Biol, 2009, 655: 159-170. doi:10.1007/978-1-4419-1132-2_12 [8] Liu S, Liu J, He Y, et al. Generation and characterization of Brucella suis S2 ghosts[J]. Chin J Zoonoses, 2012, 28(7): 679-682. (in Chinese) 刘爽, 刘军, 何永聚, 等. 布鲁氏菌S2株菌壳的制备研究[J]. 中国人兽共患病学报, 2012,28(7):679-682. [9] Zhang RA, Liu J, Jiang DW, et al. Preparation and characterization of Brucella melitensis rough vaccine strain M111 ghosts[J]. Chin J Vet Sci, 2014, 34(1): 66-69. (in Chinese) 张瑞安, 刘军, 蒋大伟, 等. 粗糙型布鲁菌M111菌壳的制备[J]. 中国兽医学报, 2014,34(1):66-69. [10] Tu FP, Chu WH, Zhuang XY, et al. Effect of oral immunization with Aeromonas hydrophila ghosts on protection against experimental fish infection[J]. Lett Appl Microbiol, 2010, 50(1): 13-17. doi:10.1111/j.1472-765X.2009.02746.x [11] Adone R, Ciuchini F, Marianelli C, et al. Protective properties of rifampin-resistant rough mutants of Brucella melitensis [J]. Infect Immun, 2005, 73(7): 4198-4204. doi:10.1128/IAI.73.7.4198-4204.2005 [12] Ding J, Pan Y, Jiang H, et al. Whole genome sequences of four Brucella strains[J]. J Bacteriol, 2011, 193(14): 3674-3675. doi:10.1128/JB.05155-11 [13] Jain S, Afley P, Dohre SK, et al. Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice[J]. Vaccine, 2014, 32(35): 4537-4542. doi:10.1016/j.vaccine.2014.06.012 [14] Zhang J, Guo F, Chen C, et al. Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice[J]. Microbiol Immunol, 2013, 57(7): 502-510. doi:10.1111/1348-0421.12065
2016, Vol. 32 
